Johnson Investment Counsel’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$845K Sell
6,691
-146
-2% -$19.2K 0.01% 492
2026
Q1
$953K Sell
6,837
-5,776
-46% -$809K 0.01% 447
2025
Q4
$1.55M Sell
12,613
-1,173
-9% -$143K 0.01% 352
2025
Q3
$1.53M Sell
13,786
-463
-3% -$52.6K 0.01% 352
2025
Q2
$1.58M Buy
14,249
+2,161
+18% +$230K 0.01% 343
2025
Q1
$1.35M Sell
12,088
-4,541
-27% -$469K 0.01% 349
2024
Q4
$1.54M Buy
16,629
+1,549
+10% +$139K 0.02% 326
2024
Q3
$1.26M Sell
15,080
-18,332
-55% -$1.4M 0.01% 355
2024
Q2
$2.29M Buy
33,412
+241
+0.7% +$16.1K 0.02% 249
2024
Q1
$2.43M Sell
33,171
-623
-2% -$47.9K 0.03% 238
2023
Q4
$2.74M Buy
33,794
+1,386
+4% +$108K 0.03% 212
2023
Q3
$2.43M Sell
32,408
-1,147
-3% -$88.2K 0.03% 211
2023
Q2
$2.59M Sell
33,555
-122
-0.4% -$9.73K 0.03% 204
2023
Q1
$2.79M Buy
33,677
+2,806
+9% +$232K 0.04% 191
2022
Q4
$2.65M Sell
30,871
-164
-0.5% -$13K 0.04% 197
2022
Q3
$1.92M Buy
31,035
+247
+0.8% +$15.6K 0.03% 227
2022
Q2
$1.9M Buy
30,788
+6,616
+27% +$410K 0.03% 234
2022
Q1
$1.44M Sell
24,172
-1,971
-8% -$126K 0.02% 286
2021
Q4
$1.9M Buy
26,143
+2,479
+10% +$171K 0.02% 252
2021
Q3
$1.65M Sell
23,664
-616
-3% -$43.3K 0.02% 258
2021
Q2
$1.67M Sell
24,280
-252
-1% -$16.8K 0.02% 247
2021
Q1
$1.59M Sell
24,532
-78
-0.3% -$5.03K 0.02% 254
2020
Q4
$1.43M Sell
24,610
-718
-3% -$43.3K 0.02% 240
2020
Q3
$1.6M Sell
25,328
-39
-0.2% -$2.71K 0.03% 209
2020
Q2
$1.95M Buy
25,367
+614
+2% +$47.1K 0.04% 186
2020
Q1
$1.85M Sell
24,753
-3,485
-12% -$241K 0.04% 183
2019
Q4
$1.83M Sell
28,238
-898
-3% -$58.5K 0.03% 208
2019
Q3
$1.85M Sell
29,136
-575
-2% -$37.6K 0.04% 199
2019
Q2
$2.01M Sell
29,711
-463
-2% -$30.5K 0.04% 198
2019
Q1
$1.96M Buy
30,174
+1,675
+6% +$111K 0.04% 203
2018
Q4
$1.78M Buy
28,499
+1,012
+4% +$70.7K 0.04% 208
2018
Q3
$2.12M Sell
27,487
-150
-0.5% -$11.3K 0.05% 202
2018
Q2
$1.96M Buy
27,637
+913
+3% +$64.5K 0.05% 196
2018
Q1
$2.01M Sell
26,724
-916
-3% -$72.8K 0.05% 180
2017
Q4
$1.98M Sell
27,640
-724
-3% -$55K 0.05% 181
2017
Q3
$2.3M Sell
28,364
-1,440
-5% -$110K 0.06% 166
2017
Q2
$2.11M Sell
29,804
-2,829
-9% -$188K 0.06% 164
2017
Q1
$2.22M Sell
32,633
-5,577
-15% -$392K 0.06% 158
2016
Q4
$2.74M Sell
38,210
-17,389
-31% -$1.29M 0.08% 145
2016
Q3
$4.4M Sell
55,599
-11,592
-17% -$942K 0.14% 112
2016
Q2
$5.61M Buy
67,191
+6,437
+11% +$571K 0.18% 98
2016
Q1
$5.58M Buy
60,754
+33,189
+120% +$2.99M 0.2% 92
2015
Q4
$2.79M Buy
27,565
+2,467
+10% +$257K 0.1% 137
2015
Q3
$2.46M Buy
25,098
+532
+2% +$59.1K 0.09% 144
2015
Q2
$2.88M Buy
24,566
+601
+3% +$65.7K 0.1% 133
2015
Q1
$2.35M Buy
23,965
+1,030
+4% +$105K 0.08% 144
2014
Q4
$2.16M Buy
22,935
+1,919
+9% +$198K 0.07% 148
2014
Q3
$2.24M Buy
21,016
+737
+4% +$72.2K 0.07% 141
2014
Q2
$1.68M Hold
20,279
0.06% 150
2014
Q1
$1.44M Buy
20,279
+483
+2% +$37.9K 0.05% 159
2013
Q4
$1.49M Sell
19,796
-229
-1% -$15.9K 0.05% 163
2013
Q3
$1.26M Buy
20,025
+371
+2% +$22.2K 0.05% 167
2013
Q2
$1.01M Buy
+19,654
New +$1.02M 0.04% 171

Other funds holding GILD

Johnson Investment Counsel's GILD Position: Q2 2026 in Review

Johnson Investment Counsel reduced its Gilead Sciences (GILD) stake by 2.1% in Q2 2026, selling an estimated $19.2K and leaving 6,691 shares worth $845K. The position accounts for 0.01% of the portfolio, ranked #492.

Johnson Investment Counsel first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. The position peaked at $5.61M in Q2 2016. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Johnson Investment Counsel held 6,691 shares of Gilead Sciences worth $845K as of Q2 2026.
  • Johnson Investment Counsel sold 146 Gilead Sciences shares in Q2 2026, an estimated $19.2K.
  • Gilead Sciences made up 0.01% of Johnson Investment Counsel's portfolio in Q2 2026, its #492 holding.
  • Johnson Investment Counsel first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
  • Johnson Investment Counsel's Gilead Sciences position peaked at $5.61M in Q2 2016.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Johnson Investment Counsel's 13F filing for Q2 2026, filed 23 Jul 2026.